(Finance) – The stock is moving slightly higher Pfizer changing hands at a negligible +0.17%, after the US pharmaceutical giant announced that it has received all regulatory approvals necessary to complete the acquisition of Seagen and expects to close the acquisition on December 14, 2023, subject to upon satisfaction of other customary closing conditions.
The weekly analysis of the stock compared toS&P 100 shows a lag behind the index in terms of the relative strength of the American pharmaceutical company based in New York, founded in 1849which performs worse than the reference market.
The short-term scenario of Pfizer highlights a decline in prices towards the 28.41 USD area with the first resistance area seen at 28.92. Expectations are for a widening of the negative phase towards the support seen at 28.12.